Trusted Resources: Education
Scientific literature and patient education texts
Standardization of 99m technetium Pyrophosphate Imaging Methodology to Diagnose TTR Cardiac Amyloidosis
source: Journal of Nuclear Cardiology
year: 2018
authors: Bokhari S, Morgenstern R, Weinberg R, Kinkhabwala M, Panagiotou D, Castano A, DeLuca A, Andrew K, Jin Z, Maurer MS
summary/abstract:Background:
Technetium pyrophosphate (99mTc-PYP) imaging to diagnose transthyretin cardiac amyloidosis (ATTR-CA) has been increasingly utilized. The objective of this study is to provide a standardized 99mTc-PYP imaging protocol to diagnose ATTR-CA.
Methods:
104 scans from 45 subjects with biopsy-proven ATTR-CA or light-chain cardiac amyloidosis (AL) were assessed. Multiple scans were obtained using different counts (750 vs 2000 K), times to acquisition (1 vs 2 to 4 hours), processing matrix (256 vs 128), and 99mTc-PYP dose. Image quality and extracardiac activity was assessed. Quantitative methods using heart-to-contralateral ratios (H/CL) and a visual semiquantitative scale were used to diagnose ATTR-CA.19 The correlation between H/CL ratios and reproducibility of semiquantitative visual scores, acquired using various imaging parameters, were evaluated.
Results:
All imaging parameters had good to excellent image quality. 750 vs 2000 K counts, 1 hour acquisition and 256 matrix, had lower extracardiac activity (P = .00018). 10 mCi of 99mTc-PYP v. higher doses showed excellent image quality and less extracardiac activity (P = .0015). Correlation of H/CL ratios was strong (r ≥ 0.92) and reproducibility of semiquantitative visual scores was high (Kappa = 95%).
Conclusion:
An imaging protocol using 750 K counts, 10 mCi of 99mTc-PYP, and a 256 matrix was chosen as the standardized imaging protocol since it provided the shortest overall study time (1 vs 2 to 4 hours) and lowest radiation exposure (3 vs 8 to 10 mSv).
organization: Columbia University Medical Center, USADOI: 10.1007/s12350-016-0610-4
read more
Related Content
-
Unexpected Manifestation of Cardiac AmyloidosisThis report discusses an unusual case of...
-
Mathew S. Maurer, MDDr. Mathew S. Maurer is medical director...
-
Left Ventricular Myocardial Deformation on Cine MR Images: Relationship to Severity of Disease and Prognosis in Ligh...Purpose: To measure left ventricular (L...
-
Emerging Treatment Landscape for Cardiac AmyloidosisThis webinar will discuss information on...
-
American Society of Nuclear Cardiology – Cardiac Amyloidosis: A Practical OverviewThe American Society of Nuclear Cardiolo...
-
Hansie M. Mathelier, MD, FACCDr. Hansie Mathelier is a Clinical Ass...
-
Webinar Presentation by Mat Maurer on Cardiac Amyloidosishttps://www.youtube.com/watch?v=SVOfge65...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.